Interestingly, we found cell lines with high expression of these miRNA target genes showed significantly lower sensitivities to multiple anti-tumor drugs (Figure 7) including AEW541, which is a IGF-1R inhibitor [51], AZD0530 (or Saracatinib), which is a dual kinase inhibitor (Src inhibitor and Bcr-Abl tyrosine-kinase inhibitor) [52], ZD-6474 (or Vandetanib), which is a kinase inhibitor of a number of cell receptors, mainly VEGFR, EGFR and the RET-tyrosine kinase [53], AZD6244 (or Selumetinib), which is a MEK inhibitor, as well as chemotherapy of Topotecan [54]. Here, RET is linked to neoplasm.